BURLINGTON, Mass.--(BUSINESS WIRE)--Decision Resources, one of the world’s leading research and advisory firms for pharmaceutical and healthcare issues, finds that, driven primarily by the launch and uptake of Human Genome Sciences/GlaxoSmithKline’s Benlysta, the systemic lupus erythematosus (SLE) drug market will increase more than seven-fold, from approximately $300 million in 2010 to more than $2.1 billion in 2020 in in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.
